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A step-economical multicomponent synthesis of
3D-shaped aza-diketopiperazines and their drug-
like chemical space analysis†
Pierre Regenass, Stéphanie Riché, Florent Péron, Didier Rognan, Marcel Hibert,
Nicolas Girard* and Dominique Bonnet*
A rapid and atom economical multicomponent synthesis of complex aza-diketopiperazines (aza-DKPs)
driven by Rh(I)-catalyzed hydroformylation of alkenylsemicarbazides is described. Combined with catalytic
amounts of acid and the presence of nucleophilic species, this unprecedented multicomponent reaction
(MCR) enabled the formation of six bonds and a controlled stereocenter from simple substrates. The
eﬃcacy of the strategy was demonstrated with a series of various allyl-substituted semicarbazides and
nucleophiles leading to the preparation of 3D-shaped bicyclic aza-DKPs. Moreover, an analysis of their
3D molecular descriptors and “drug-likeness” properties highlights not only their originality in the chemi-
cal space of aza-heterocycles but also their great potential for medicinal chemistry.
Introduction
Low molecular-weight organic molecules are a major source of
pharmacological probes and/or drug candidates.1 Recent
achievements in Pd-catalyzed C(sp2)–C(sp2) coupling reactions
have greatly facilitated the syntheses of small-size com-
pounds.2,3 While these advances have largely contributed to
drug discovery, mainly compounds with greater unsaturation,
aromaticity and flatness were obtained.4 But, as recently
reported, such compounds are less likely to succeed in clinical
trials than saturated ones.5 Indeed, increasing saturation in
molecules results in more complex three dimensional 3D-
shaped structures with greater potential to better complement
the spatial subtleties of target proteins, thus increasing their
selectivity and reducing oﬀ-target liabilities. In addition, satu-
ration also greatly improves aqueous solubility and as a conse-
quence ameliorates pharmacokinetic properties while
decreasing potential toxicity. Finally, it has been observed that
the number of stereogenic centers increases from early hit dis-
covery to late drug candidate stages, highlighting the impor-
tance of molecular complexity in drug development.4
In this context, we embarked on a general programme
aiming to design eﬃcient and facile routes to complex 3D-
shaped molecules containing sp3 hybridized carbons and
stereocenters with potential application in medicinal chem-
istry. Indeed, we described recently the access to novel aza-
diketopiperazine (aza-DKP) scaﬀolds, which represent the
smallest cyclo aza-peptides described to date (Fig. 1, series A).6
Relying on a cyclohydrocarbonylation (CHC)/addition process,
we also synthesized a range of bicyclic and tricyclic aza-DKPs
incorporating six- or seven-membered rings appended with
defined stereocenters (Fig. 1, series B and C).7 Herein, we
report an unprecedented and highly eﬃcient one-pot sequence
to readily access aza-DKPs. For the first time, alkenyl-substi-
tuted semicarbazides were subjected to a Rh(I)-catalyzed hydro-
formylation.8 This multicomponent reaction (MCR) performed
under acid catalysis and in the presence of various nucleo-
philes enabled the one-pot formation of six bonds and one
stereocenter. Thereby, this step and atom economical
approach was advantageously applied to the preparation of a
range of aza-DKPs. In addition, their 3D molecular descriptors
and “drug-likeness” properties were carefully evaluated to
determine not only their originality in the chemical space of
existing scaﬀolds but also their propensity to succeed in poten-
tial future clinical trials.
Fig. 1 Chemical structures of recently synthesized aza-DKP scaﬀolds.6,7
†Electronic supplementary information (ESI) available: Detailed experimental
procedures and analytical data for all the compounds. See DOI: 10.1039/
c6ob01434h
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Results and discussion
While DKPs represent an important heterocyclic core present
in synthetic and natural products, their nitrogen analogues,
aza-DKPs, are less well-known and provide interesting opportu-
nities for lead discovery. To access this novel class of underpri-
vileged scaﬀold, very few practical synthetic routes are
available.9,10 For bicyclic or tricyclic aza-DKPs B and C (Fig. 1),
the only synthetic approach reported to date involves a four-
step process starting from alkyl-amino esters.6 Thereby, to
facilitate the access to diverse aza-DKPs 4, we decided to
develop a rapid and convenient approach that relies on an un-
precedented MCR encompassing five transformations from
semicarbazides 1 (Scheme 1).
A novel multicomponent reaction
Firstly, to develop this novel approach, we needed to evaluate
the fate of semicarbazides 1 upon hydroformylation
(Scheme 2). Thus, semicarbazide model 1a, readily obtained
from N-alkyl amino ester,6 was subjected to hydroformylation
in the presence of Rh(CO)2(acac)/BiPhePhos,
11,12 CO/H2 (1 : 1,
5 bar) and pyridinium p-toluenesulfonate (PPTS). Under these
experimental conditions, 1a was converted into tetrahydropyri-
dazine 5 in excellent yield (90%). This result not only shows
that the hydroformylation is compatible with semicarbazides
of type 1 but also shows that the Boc protected secondary
amine is nucleophilic enough to spontaneously promote the
cyclization with the aldehyde moiety to form the iminium
intermediate. Interestingly, the resulting original unsaturated
terahydropyridazine 5 can be viewed as a precursor of topo-
graphically constrained α-aza-amino acids.13 Then, the nucleo-
philic addition of MeOH to 5 in the presence of PPTS (0.5 equiv.)
gave access to 6 in good yield (78%) but a low dr (60 : 40). The
treatment of the latter in the presence of a strong acid (CSA,
0.5 equiv.) in MeOH at 70 °C initiated a second cyclization
towards 4a, which was obtained in good yield (78%) and, more
surprisingly, a much greater diastereoselectivity than that
obtained for 6 (93 : 7 vs. 60 : 40, respectively). This result could
be ascribed to the reversibility of the hemiaminal formation
under strongly acidic conditions likely evolving towards the
thermodynamically more stable trans-isomer. To support this
result, the energy diﬀerences (ΔH based on MM2 calculations)
between the cis and the trans isomers for 6 and 4a were evalu-
ated. Minimized structures for each diastereoisomer are
depicted in the ESI.† Thereby, the energy diﬀerence for 6 is
1.39 kcal mol−1, resulting in the formation of both isomers
with a lower dr than for 4a that displays a higher ΔH (2.01
kcal mol−1) in favor of the trans isomer. In search of a method for
reducing the number of steps, we found that tetrahydropyrida-
zine 5 could also be advantageously treated with CSA (0.5
equiv.) in MeOH to directly lead to 4a in good yield (70%) and
high diastereoselectivity (93 : 7). Thus, bicyclic aza-DKP 4a was
obtained from semicarbazide 1a in a two-step sequence in
63% overall yield. After validating the hydroformylation on
allyl-substituted semicarbazide, we focused our attention on
the development of a multicomponent reaction to straight-
forwardly convert 1a into 4a. The optimized experimental con-
ditions determined above were advantageously combined.
Thereby, 1a was treated in the presence of CSA and the Rh/
BiPhePhos complex under catalytic conditions in MeOH/THF
at 70 °C under 5 bar of CO/H2 (Table 1, entry 1). In our first
attempt, we were pleased to obtain the expected bicyclic aza-
DKP 4a. It is noteworthy that the concentration of CSA in
Scheme 1 A novel MCR strategy towards heterocyclic aza-DKP
scaﬀold 4.
Scheme 2 Two-step process from semicarbazide 1a to aza-DKP 4a.
Table 1 MCR towards aza-heterocycles 4a–f
Entry
Amino
acid R1 R2 n
Yielda
(%) dr (trans/cis)b
1 L-Ala (S)-Me Bn 1 4a (69) 93 : 7
2 L-Ile (S)-sec-Bu Bn 1 4b (48) >99 : 1
3 L-Ala (S)-Me iPe 1 4c (32) >95 : 5
4 L-Phe (S)-Bn Bn 1 4d (31) >95 : 5
5 L-Lys(Boc) (S)-H2N(CH2)4 Bn 1 4e (25)
c >95 : 5
6 L-Ala (S)-Me Bn 2 4f (52) 37 : 63
a Isolated yields. bDiastereomeric ratios were determined by 1H NMR
or HPLC analysis of the crude reaction mixtures. c 1.5 equiv. of CSA
were used instead of 0.5 equiv.
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MeOH/THF was found to be crucial for driving the one-pot
sequence to completion. After optimization, 4a was obtained
in good yield (69%) and the same dr (93 : 7) as that described
above.
Scope and limitations of the multicomponent reaction
With these promising results in hand, the scope and limit-
ations of the MCR were then evaluated. To this end, the
sequence was extended to other semicarbazides (1b–f ) that
were obtained in moderate to good yields (37 to 82%) from the
corresponding N-alkyl amino acid esters. These substrates
were then subjected to the optimized conditions mentioned
above for the MCR. Isolated yields and dr for all compounds
4a–f are summarized in Table 1. In all cases, the expected
bicyclic compounds were obtained in yields ranging from 25%
to 69% and a high diastereoselectivity. The process was com-
patible with the presence of bulky substituents at R1 and R2
(Table 1, entries 2 and 3) or aromatic ones (entry 4).
Functional groups such as amines (entry 5) were also tolerated
and did not interfere with the Rh/BiPhePhos complex eﬃcacy.
Remarkably, the cyclization to a seven-membered ring (entry 6)
was also found successful but with a lower stereoselectivity.
This result can be ascribed to the energy diﬀerence between
the two isomers (0.05 kcal mol−1), much below 2 kcal mol−1.
Altogether, these results demonstrate that this process rep-
resents a convenient atom- and step-economical route for the
preparation of complex 3D-shaped bicyclic structures starting
from simple and readily accessible allyl- or homoallyl-substi-
tuted semicarbazides.
Extension to other nucleophiles
To further extend the scope of the MCR, various nucleophilic
species were evaluated (Table 2). To this end, semicarbazide 1a
was subjected to the same one-pot sequence experimental con-
ditions as those described above by replacing MeOH by EtOH,
nPrOH, iPrOH, TMSCN or nPrSH. In the alcohol series, the
eﬃciency of the reaction was clearly correlated to the hindered
character of the nucleophile (Table 2). Indeed, whereas hemi-
aminal 4a (R4 = OMe, Table 1, entry 1) and 4g (R4 = OEt, entry 1)
were obtained in good yields (69% and 65%, respectively),
the reaction was found sluggish with more hindered R4 such
as OnPr or OiPr. In this case, increasing the amount of CSA (1
equiv. vs. 0.5 equiv.) enabled us to greatly improve the eﬃcacy
of the process (Table 2, entries 2 and 3). Regardless of the
nature of the alcohol, aza-DKPs were obtained with good
stereoselectivities. Finally, hydroformylation performed in the
presence of nPrSH or TMSCN failed to give 4j and 4k. Both
nucleophiles were found to compete as a ligand for rhodium,
leading to the inactivation of the Rh/BiPhePhos complex. To
overcome this limitation, hydroformylation was first achieved
before adding the nucleophilic species (nPrSH or TMSCN/
BF3·OEt2), thus leading to the expected aza-DKPs 4j and 4k
(Table 2, entries 4 and 5) in good yield (71% and 79%, respect-
ively) but a low diastereoselectivity (73 : 27 and 55 : 45,
respectively).
In an attempt to explain the diﬀerence of dr between the
aza-DKPs, the reversibility of the nucleophilic addition was
carefully investigated. Thus, the treatment of aza-DKPs 4g
(R4 = OEt) and 4j (R4 = SnPr) in methanol in the presence of
CSA at 70 °C led to 4a in the same isomeric ratio as those
obtained during the MCR. This result tends to demonstrate that
the nucleophilic addition is reversible and under thermo-
dynamic control. The theoretical calculations of energy diﬀer-
ence performed on both diastereoisomers of 4g–j (4g: ΔH =
2.13 kcal mol−1; 4h: ΔH = 3.83 kcal mol−1; 4i: ΔH = 4.65 kcal
mol−1; 4j: ΔH = 1.80 kcal mol−1) are in agreement with the dr
experimentally obtained. In contrast, aza-DKP 4k treated under
the same conditions (CSA, MeOH, 70 °C) was found fully stable
and did not result in the formation of 4a. In this case, the
addition of CN species on the iminium intermediate is likely
under kinetic control, only leading to the formation of aza-DKP
4k with a low selectivity.
3D molecular shape and “drug-likeness” properties of aza-
DKPs
Once the novel MCR was developed, we wanted to evaluate the
“drug-likeness” properties of the two model aza-DKP scaﬀolds
4a and 4f, incorporating six- and seven-membered rings,
respectively. As previously reported, the clinical success of
drug candidates is greatly influenced by their physicochemical
properties, among which one of the most important is mole-
cular shape.14 It has been shown that two dimensional (2D)
molecular descriptors such as the fraction of hybridized sp3
carbon atoms (Fsp3) and the number of stereocenters correlate
with clinical success.5 In addition, shape-based 3D descriptors
such as the radius of gyration (ROG) and shadow indices
(Shadow Xlength, SXL) explicitly describe the compactness and
flatness of a compound, and therefore represent an eﬃcient
way to evaluate the propensity of a compound to advance from
clinical trials to the market.15 Although predictions based
solely on physicochemical properties should be taken with
Table 2 Extension of the MCR to other nucleophiles
Entry R4 Yielda (%) dr (trans/cis)b
1 OEt 4g (65) >95 : 5
2 OnPr 4h (47)c >95 : 5
3 OiPr 4i (46)c >95 : 5
4 SnPr 4j (71)d 73 : 27
5 CN 4k (79)d 55 : 45
a Isolated yields. bDiastereomeric ratios were determined by 1H NMR
and/or HPLC analysis of the crude reaction mixtures. c 1 equiv. of CSA
was used instead of 0.5 equiv. d Reaction performed without CSA;
nPrSH or BF3·Et2O/TMSCN was added after 7 h of reaction.
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care, drug candidates successfully advancing to clinical trials
tend to share the following properties: SXL ≤ 16.09; ROG <
4.11; Fsp3 ≥ 0.42. Additionally, the chance of a preclinical can-
didate passing through the diﬀerent clinical trial stages was
also evaluated by the quantitative estimate of the drug-likeness
(QED) descriptor. Compared to the classical rule-based
approaches, QED oﬀers a more nuanced view of drug-likeness.
QED values range from zero (all properties unfavorable) to one
(all properties favorable).16
Thereby, these descriptors were calculated for model aza-
DKP trans-isomers 4a and 4f. As outlined in Table 3, both com-
pounds meet the three abovementioned criteria (SXL, ROG
and Fsp3) and display an excellent QED of 0.870 and 0.881,
respectively. These results show that the novel 3D-shaped aza-
DKPs gather ideal 2D and 3D molecular characteristics to
succeed in the diﬀerent stages of drug development, provided
that these compounds eﬃciently bind to a target of thera-
peutic value and are not recognized by undesired oﬀ-targets.
To further evaluate the originality of the aza-DKPs herein syn-
thesized, we decided to compare the molecular shape of our
bicyclic scaﬀolds incorporating six- and seven-membered rings
with other heterocyclic platforms already described in the lit-
erature. To this end, the ROG values for unsubstituted aza-
DKP scaﬀolds D and E were plotted as a function of the Fsp3
value and compared with that of 9266 unique homo and
heterocyclic scaﬀolds derived from 5 million commercially
available drug-like compounds for which a low energy 3D
structure was taken as the reference (Fig. 2). Some representa-
tive scaﬀolds with extreme properties are also shown to illus-
trate the plot.
Thus, scaﬀolds D and E display a very high Fsp3 value, and
are interestingly located in a sparsely populated area in our 2D
representation of drug-like scaﬀold space (Fig. 2, top right
hand corner). Of particular interest, scaﬀolds D and E com-
plement the molecular diversity of already existing heterocyclic
scaﬀolds (some representative ones with extreme properties)
but also display optimal “drug-likeness” properties to poten-
tially succeed in the diﬀerent stages of clinical trials.
Conclusion
The preparation of highly diverse and “out-of-plane” scaﬀolds
requires the design of eﬃcient, rapid and facile synthetic
routes. In this article, we describe for the first time the suc-
cessful application of Rh(I)-catalyzed cyclohydroformylation to
allyl- and homoallyl-substituted semicarbazides. Combined
with catalytic amounts of acid and the presence of nucleo-
philic species, the unprecedented MCR enabled the formation
of six bonds and a controlled stereocenter. The eﬃcacy of the
strategy was demonstrated with a series of various allyl-substi-
tuted semicarbazides and nucleophiles leading to the rapid
preparation of 3D-shaped bicyclic aza-DKPs. Thus, this process
represents an advance in the field of the diversity-oriented syn-
thesis of novel aza-heterocycles. In addition, the analysis of
their 3D molecular descriptors and “drug-likeness” properties
highlighted not only their originality in the chemical space of
aza-heterocycles but also their high propensity to succeed in
potential future clinical trials.
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Table 3 3D molecular descriptors and QED of aza-DKP 4a and 4f
Cpd Shadow Xlengtha Radius of gyrationa Fsp3
a QEDb
4a 13.079 3.638 0.500 0.870
4f 13.653 3.867 0.529 0.881
a ROG, SXL and Fsp3 were calculated as reported in D. C. Kombo, et al.,
J. Chem. Info Model., 2013, 53, 327–342. b The quantitative estimate of
drug-likeness was calculated as reported in G. R. Bickerton, et al.16
Fig. 2 2D plot of current drug-like scaﬀold space. Scaﬀolds were
deﬁned, from our in house collection of 5 million commercially available
drug-like compounds (http://bioinfo-pharma.u-strasbg.fr), as any
unique ring, ring assembly (contiguous rings) or bridge assembly (con-
tiguous rings sharing two or more bonds) detected by the ‘Generate
Fragment’ component of Pipeline Pilot 9.5 (Dassault Systèmes BIOVIA
Corp, Vélizy-Villacoublay, France). A total of 9266 unique scaﬀolds are
shown, along with our two aza-DKP scaﬀolds D and E in a 2D plot using
the radius of gyration (ROG) and the fraction of hybridized sp3 carbon
atoms (Fsp3) as descriptors. Some representative scaﬀolds with extreme
properties are displayed to illustrate the plot.
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